Advance online publication

The latest articles are published online ahead of print (AOP) on a weekly basis. These online versions are definitive and may be cited using the digital object identifier (DOI).


23 June 2017

News and Analysis

From the analyst's couch

The multiple sclerosis market | PDF (214 KB)

Published online: 23 June 2017 | doi:10.1038/nrd.2017.107

This article discusses the impact of new drugs on the market for multiple sclerosis, including the recently approved immunomodulatory drug ocrelizumab and drugs in development such as sphingosine 1-phosphate receptor modulators and neurorestorative agents.


16 June 2017

News and Analysis

Biobusiness Briefs

Market watch: Upcoming market catalysts in Q3 2017 | PDF (83 KB)

Published online: 16 June 2017 | doi:10.1038/nrd.2017.117


Research Highlights

Endocrinology: Reducing fat and building bone | PDF (274 KB)

Published online: 16 June 2017 | doi:10.1038/nrd.2017.121

Ageing: Old bone removal | PDF (201 KB)

Published online: 16 June 2017 | doi:10.1038/nrd.2017.123

In brief

Cancer: Targeting MYC-driven translation | PDF (81 KB)

Published online: 16 June 2017 | doi:10.1038/nrd.2017.118

Genetic disorders: Repurposing metformin in FXS | PDF (81 KB)

Published online: 16 June 2017 | doi:10.1038/nrd.2017.119

G Protein-Coupled Receptors: Crystal structure of glucagon family receptors | PDF (81 KB)

Published online: 16 June 2017 | doi:10.1038/nrd.2017.120


09 June 2017


Breaking barriers to novel analgesic drug development

Ajay S. Yekkirala, David P. Roberson, Bruce P. Bean & Clifford J. Woolf

Published online: 09 June 2017 | doi:10.1038/nrd.2017.87

Existing pain therapies are often inadequate or associated with side effects. Here, Woolf and colleagues discuss new and existing strategies for the development of improved pain therapeutics, highlighting key challenges and considerations in the clinical development of novel analgesics.


26 May 2017

News and Analysis

From the analyst's couch

The ovarian cancer drug market | PDF (169 KB)

Published online: 26 May 2017 | doi:10.1038/nrd.2017.92

This article discusses the impact of the recent approvals of poly ADP ribose polymerase (PARP) inhibitors on the market for ovarian cancer drugs, as well as potential future treatments such as immunotherapies.


19 May 2017

News and Analysis

From the analyst's couch

Colorectal cancer drugs market | PDF (179 KB)

Published online: 19 May 2017 | doi:10.1038/nrd.2017.59

The market for colorectal cancer therapies, which is currently dominated by drugs targeting vascular endothelial growth factor and epidermal growth factor receptor, is poised for change with the anticipated entry of immunotherapies and other targeted drugs.



Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles

Lorenzo Galluzzi, José Manuel Bravo-San Pedro, Beth Levine, Douglas R. Green & Guido Kroemer

Published online: 19 May 2017 | doi:10.1038/nrd.2017.22

Dysregulated autophagy is associated with a variety of conditions, including cancer, neurodegenerative diseases, cardiovascular disorders and infectious diseases. However, despite significant efforts, no specific modulators of autophagy have yet been moved into the clinic. Here, Galluzzi et al. discuss the therapeutic potential of autophagy modulators and consider the key challenges that have limited their development.

Therapeutic targeting of the angiopoietin–TIE pathway

Pipsa Saharinen, Lauri Eklund & Kari Alitalo

Published online: 19 May 2017 | doi:10.1038/nrd.2016.278

The angiopoietin (ANG)–TIE growth factor receptor pathway regulates pathological vascular remodelling during inflammation, tumour angiogenesis and metastasis. It has become an attractive pharmacological target for oncological and ophthalmological indications, as well as sepsis, diabetic vasculopathies, organ transplantation and atherosclerosis. Here, Alitalo and colleagues provide an overview of the biology of the ANG–TIE pathway and discuss the development of therapeutics that target it.


12 May 2017

Comment: Combination products: modernizing the regulatory paradigm

Nina L. Hunter & Rachel E. Sherman

Published online: 12 May 2017 | doi:10.1038/nrd.2017.66

New opportunities to develop innovative — and often complex — products that combine drugs, devices and/or biological components are rapidly emerging, raising questions about how such products should be regulated. Here, we discuss the ongoing efforts of the FDA to develop a modern, transparent, flexible and consistent science-based regulatory approach for combination products.



The antifungal pipeline: a reality check

John R. Perfect

Published online: 12 May 2017 | doi:10.1038/nrd.2017.46

Invasive fungal infections are a major medical concern, particularly in immunocompromised patients. In this Review, Perfect discusses the antifungal pipeline, including advances in the currently used drug classes, novel molecular targets, drugs that could be repurposed from other areas and the use of immune-directed therapies.


05 May 2017

News and Analysis

Biobusiness Briefs

Market watch: Landscape for medical countermeasure development | PDF (131 KB)

Published online: 05 May 2017 | doi:10.1038/nrd.2017.80



Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond

Veaceslav Boldescu, Mira A. M. Behnam, Nikos Vasilakis & Christian D. Klein

Published online: 05 May 2017 | doi:10.1038/nrd.2017.33

Flaviviruses, including dengue and Zika viruses, are of substantial public health concern. Klein and colleagues review the development of broad-spectrum antiviral agents that would target many of the known and potentially unknown flaviviruses. The benefits and caveats of molecules that target either viral proteins or host mechanisms exploited by these viruses are discussed.


28 April 2017

Comment: Implications of cancer evolution for drug development

Samra Turajlic & Charles Swanton

Published online: 28 April 2017 | doi:10.1038/nrd.2017.78

Tumour evolution, which results in the existence of multiple distinct populations of cancer cells within the same tumour and the same patient, is increasingly appreciated to have a key role in drug resistance. In this article, we discuss the implications for drug development, including approaches to reduce the likelihood of the emergence of drug resistance.

Comment: Bridging the translational innovation gap through good biomarker practice

Alain J. van Gool, Florence Bietrix, Eric Caldenhoven, Kurt Zatloukal, Andreas Scherer, Jan-Eric Litton, Gerrit Meijer, Niklas Blomberg, Andy Smith, Barend Mons, Jaap Heringa, Wim-Jan Koot, Martin J. Smit, Marian Hajduch, Ton Rijnders & Anton Ussi

Published online: 28 April 2017 | doi:10.1038/nrd.2017.72

Few biomarkers progress from discovery to become validated tools or diagnostics. To bridge this gap, three European biomedical research infrastructures — EATRIS-ERIC (focused on translational medicine), BBMRI-ERIC (focused on biobanking) and ELIXIR (focused on data sharing) — are paving the way to developing and sharing best practices for biomarker validation.


24 March 2017


Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance

Seth W. Dickey, Gordon Y. C. Cheung & Michael Otto

Published online: 24 March 2017 | doi:10.1038/nrd.2017.23

Efforts to combat bacterial infections by targeting virulence factors are gaining traction, fuelled by the potential to circumvent the development of antibacterial resistance and recent landmark approvals of antivirulence drugs. Here, Otto and colleagues examine the antivirulence drugs in development, highlighting the most promising targets and strategies, as well as caveats to using this approach.


17 March 2017


Targeting glutamate signalling in depression: progress and prospects

James W. Murrough, Chadi G. Abdallah & Sanjay J. Mathew

Published online: 17 March 2017 | doi:10.1038/nrd.2017.16

Changes in glutamate signalling have been implicated in major depression, and ketamine, which was recently found to act as a rapid-acting antidepressant, affects glutamate signalling in several ways. Murrough and colleagues give an overview of the development of glutamate-signalling modulators for depression and examine studies on the mechanisms of these agents.


12 September 2016

Corrigendum: Impact of genetically supported target selection on R&D productivity

Mark R. Hurle, Matthew R. Nelson, Pankaj Agarwal & Lon R. Cardon

Published online: 12 September 2016 | doi:10.1038/nrd.2016.187


About AOP

Until print versions of AOP papers are published, they should be cited in the style "Nature Reviews Drug Discovery AOP, published online day month year; doi:10.1038/nrdXXX". Once the print version (identical to the AOP) is published, it should be cited as follows: "Nature Reviews Drug Discovery volume number, page range (year); doi:10.1038/nrdXXX".

Extra navigation